BTAI Projected Dividend Yield
BioXcel Therapeutics Inc ( NASDAQ : BTAI )BioXcel Therapeutics, Inc. is a biopharmaceutical company leveraging artificial intelligence to develop medicines in neuroscience and immuno-oncology through its subsidiary, OnkosXcel Therapeutics. Co.'s neuroscience candidate, BXCL501, is an investigational, orally dissolving film for treating agitation in psychiatric and neurological disorders, including bipolar disorders, schizophrenia and Alzheimer's-related dementia, for both at-home and care facility settings. Co.'s immuno-oncology candidate, BXCL701, is an oral innate immune activator aimed at treating aggressive prostate cancer, pancreatic cancer and other solid and liquid tumors. 21 YEAR PERFORMANCE RESULTS |
BTAI Dividend History Detail BTAI Dividend News BTAI Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |